Abstract Antigen uptake by dendritic cells and intracellular routing of antigens to specific compartments is regulated by C-type lectin receptors that recognize glycan structures. We show that the modification of Ovalbumin (OVA) with the glycan-structure Lewis X (Le X ) re-directs OVA to the C-type lectin receptor MGL1. Le X -modification of OVA favored Th1 skewing of CD4 + T cells and enhanced cross-priming of CD8 + T cells. While cross-presentation of native OVA requires high antigen dose and TLR stimuli, Le X modification reduces the required amount 100-fold and obviates its dependence on TLR signaling. The OVA-Le X -induced enhancement of T cell cross-priming is MGL1-dependent as shown by reduced CD8 + effector T cell frequencies in MGL1-deficient mice.
Introduction
The induction of T cell immunity to viruses or tumors involves the presentation of viral or tumor antigens by antigen-presenting cells (APC) in the context of major histocompatibility complex (MHC) molecules. Loading of exogenously-derived antigens onto MHC class I molecules, a process known as cross-presentation (Carbone and Bevan, 1990 ) is required to activate antigen-specific CD8 + T cells. Furthermore, cognate CD4 + T cell help is important for licensing the APC, which is essential for effective CD8 + T cell priming and induction of long-lasting memory (Bennett et al., 1997; Schoenberger et al., 1998) . The molecular mechanisms underlying cross-presentation have been studied intensively, however, little is still known on the nature of the antigens and stimuli that are required for APC to route exogenous antigens efficiently into the MHC class I presentation pathway. Most exogenous antigens that originate from tumor cells or viruses are glycosylated in their native form (Apweiler et al., 1999) . The relative composition of the glycosylation machinery, which includes all the necessary glycosylation-related enzymes and co-factors, determines the final configuration of the glycan structures that decorate N-or O-linked glycosylation sites present in glycoproteins. The glycosylation machinery can be affected by multiple physio-pathological cues, including proliferation, activation, and the transformation status of the cell (Ohtsubo and Marth, 2006) , and depends on environmental factors. APC, such as dendritic cells (DCs) and macrophages are able to sense glycans exposed on either self-or pathogen-derived antigens via glycan-binding proteins. Amongst these glycan-binding proteins are C-type lectin receptors (CLRs) that recognize defined carbohydrate-structures through their carbohydrate recognition domain (CRD). Depending on the amino acid sequence, the CRD bears specificity for mannose, fucose, galactose, sialylated-, or sulfated structures. CLRs function both as antigen uptake and/or signaling receptors that modify DCinduced cytokine responses thereby influencing T cell differentiation (van and Rabinovich, 2008) . The specialized internalization motifs in the cytoplasmic domains of CLRs allow the rapid internalization of antigens upon interaction (Engering et al., 2002; Herre et al., 2004) . This suggests that DCs use CLRs to 'sense' the natural glycan composition of tissues and invading pathogens and, in response to this recognition, are able to modulate immune responses (Geijtenbeek and Gringhuis, 2009) .
The conjugation of antigens to CLRs-specific antibodies, such as DEC205, mannose receptor (MR), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) or CLEC9A, has proven to be an effective way to direct antigens to DCs, resulting in enhanced antigen uptake and presentation on MHC molecules (Bonifaz et al., 2004; Hawiger et al., 2001; Caminschi et al., 2008; Chatterjee et al., 2012) . Also glycans specific for CLRs have shown their targeting specificity and potential to improve antigen uptake and presentation in MHC class I and II molecules when coupled to antigen formulations (Singh et al., 2009a; Garcia-Vallejo et al., 2013; Unger et al., 2012; Unger, 2014; Aarnoudse et al., 2008; Yang et al., 2008; Singh et al., 2011) . To achieve immunity rather than tolerance inclusion of a strong adjuvant is necessary. Little is known on how naturally glycosylated antigens or alterations in the glycosylation of antigens may change and re-direct antigen internalization via CLRs, in addition to subsequent processing and presentation.
MR was shown to mediate cross-presentation of the model-antigen ovalbumin (OVA) in a Toll-like receptor (TLR)-dependent manner and to recruit TAP-1 to endocytic organelles (Burgdorf et The experiments show that injecting mice with Ovalbumin-Lewis X triggers a much stronger immune response than normal Ovalbumin does. This enhanced response was not observed in mice that lacked the MGL1 receptor, which suggests that this receptor is involved in detecting Ovalbumin-Lewis X . Furthermore, the dendritic cells store the altered Ovalbumin for longer than they store normal Ovalbumin, which gives the cells more time to present the altered Ovalbumin to other immune cells.
Vaccines and some other therapies help to boost immune responses to viruses and tumors by exposing the body to antigens. However, these therapies often use antigens that don't have sugar molecules attached to them, or are missing the sugar molecules they would normally have. StrengOuwehand et al.'s findings suggest that adding specific sugars to antigens in immune therapies might help to make these therapies more effective.
2007; . Importantly, cross-presentation of OVA was only effective using high amounts of antigen (Burgdorf et al., 2007; . The interaction of OVA with MR, which has specificity for mannose (Taylor et al., 1992) , was speculated to be dependent on the presence of mannose glycans on OVA (Burgdorf et al., 2007) . In the current study, we investigated the effect of modifying the glycan composition of OVA on the efficacy of cross-presentation, priming and differentiation of T cells. We hypothesized that modification of the antigen with specific glycans would re-direct antigens to other CLRs resulting in altered intracellular routing and presentation of antigen and Th differentiation. We have chosen to conjugate the carbohydrate structure Lewis X (Le  X ) to 2 free cysteine residues within the native OVA glycoprotein. Le X is a ligand of the murine C-type lectin macrophage galactose-type lectin (MGL)-1 (Singh et al., 2009b) , which is expressed on murine plasmacytoid DC, CD8 + and CD8 -splenic DC, DC in the small intestines, the sub-capsular and intrafollicular sinuses of T cell areas in lymph nodes, and on DC and macrophages in the dermis of skin (Dupasquier et al., 2006; Tsuiji et al., 2002; Denda-Nagai et al., 2010; Segura et al., 2010) . Murine MGL1 is one of two homologues (MGL1 and MGL2) of human MGL (huMGL), which has been shown to interact with tumor cells through glycans exposed on MUC1 as well as with various pathogens (van Vliet et al., 2008) . However, MGL1 and MGL2 bind different glycan structures: while MGL1 binds Le X and Le a glycans, MGL2 binds N-acetylgalactosamine (GalNAc) and galactose glycan structures (Singh et al., 2009b) . The YENF motif in the cytoplasmic tail of huMGL is essential for uptake of soluble antigens, which are subsequently presented to CD4 + T cells (van Vliet et al., 2007) . Murine MGL1 contains a similar motif (YENL) in its cytoplasmic tail, which likely plays a similar and important role in antigen uptake (Yuita et al., 2005) . Glycan binding to the CLRs DC-SIGN, Dectin-1 and Dectin-2 has been demonstrated to trigger the signaling capacity of these receptors, modulating DC-mediated T helper cell (Th) differentiation and cytokine production by DCs (Geijtenbeek and Gringhuis, 2009 ). This illustrates that glycan epitopes may not only improve antigen presentation, but may also affect Th differentiation and shape specific adaptive immune responses. This is underlined by the observation that DC-SIGN signaling induced upon sensing of specific mannose or fucose structures on pathogens differentially directed Th differentiation (Gringhuis et al., 2014) .
Here, we demonstrate that conjugation of the Le X carbohydrate to the model antigen OVA alters its routing from a MR-and TAP1-dependent cross-presentation pathway into a TAP1-and Cathepsin-S-independent pathway, devoid of any TLR-signaling dependence, which simultaneously enhanced CD8 + T cell priming and Th1 skewing of CD4 + T cells. Cross-presentation was associated with prolonged intracellular storage of antigen in Rab11 + LAMP1 + vesicles. Our results illustrate that small changes in the glycosylation profile of protein antigens can have a great impact on antigen routing within DCs, affecting cross-presentation and Th cell differentiation.
Results
Identification of glycans on native and glycan-modified OVA, and the consequences for CLR-specific binding and cross-presentation
The well-known model antigen OVA carries one N-glycosylation site at N293 and, although the variety of OVA glycans have been previously described, their relative abundance has never been characterized in detail. We determined the glycan profile of OVA by normal-phase HPLC coupled with electrospray ionization mass spectrometry with an intercalated fluorescence detector. We found that the majority of glycan species on OVA corresponded to the complex-type (54.9%), while mannoserich glycans (mainly Man5 and Man6, potential ligands of the MR (Taylor and Drickamer, 1993) ) represented only 23% of all glycoforms ( Figure 1A) . The remaining glycoforms were of the hybrid (16.2%) and oligomannose (Man3, 3%) type. The presence of mannose rich glycans on OVA correlate with the earlier reports that in particular MR interacted with OVA (Burgdorf et al., 2006) and mediated the TLR dependent and TAP-1 dependent cross-presentation of OVA . We reasoned that the conjugation of additional glycans to OVA would alter its CLR-dependent effects. To do this, we conjugated the tri-saccharide glycan structure Le X (Galb1-4(Fuca1-3)GlcNAc)
to the free cysteins of OVA using standard thiol-maleimide chemistry via the bifunctional crosslinker MPBH. Le X is a well characterized carbohydrate ligand of the C-type lectin MGL1 (Hawiger et al., 2001; Singh et al., 2009b) . Using mass spectrometry (MALDI-TOF/TOF), we confirmed that OVA-Le X increases to 1.2 KDa in mass, indicating that at least 40% of the total OVA-Le X preparation contained the Le X ( Figure 1-figure supplement 1 ). This increase corresponded to the addition of two Le X molecules per OVA molecule.
Furthermore, using anti-Le X antibodies the presence of Le X was detected on OVA-Le X , whereas absent on native glycosylated OVA, indicating that the glycan was successfully conjugated to OVA ( Figure 1B) . While native OVA interacted with the MR (MR-Fc, Figure 1B ) and as earlier described (Burgdorf et al., 2007) , the conjugation of Le X to OVA conferred high-avidity binding to MGL1 as revealed using the soluble recombinant form of MGL1 (MGL1-Fc, Figure 1B) . Moreover, the addition of Le X to OVA did not result in increased binding to the MR binding, indicating that Le X selectively binds MGL1. Similar binding with an anti-OVA antibody was determined, which indicates that similar protein concentrations in the preparations of OVA and OVA-Le X used in our study are present ( Figure 1B , right panel). In conclusion, through glycan profiling we identified 23% mannose-rich glycans on native OVA that may facilitate MR binding. Addition of the glycan Le X , next to these mannose glycans, on cysteine residues (two Le X moieties per molecule), conveyed MGL1 specificity to OVA.
OVA-Le X binds MGL1 and augments priming of OVA-specific CD8 + T cells in-vivo OVA-Le X induces Th1 skewing of naive CD4 + T cells
Since we observed that Le X -modified OVA increased priming of antigen-specific CD8 + T cells we examined whether this also enhanced antigen-presentation to CD4 + T cells. Both OVA-Le X -loaded and native OVA-loaded spDCs induced CD4 + OT-II T cell proliferation to a similar extent ( Figure 3A) , illustrating that the altered antigen uptake mediated by Le X did not affect loading on MHC class II molecules. Similar results were obtained using BM-DCs ( Figure 3A) . Although we did not observe any differential effect of Le X on CD4 + T cell expansion, neoglycosylation of antigens could induce signaling via CLRs and herewith potentially influence Th cell differentiation (Gringhuis et al., 2014) . We therefore investigated whether OVA-Le X affected the differentiation of naive CD4 + T cells. Hereto BM-DCs and spDCs of C57BL/6 mice were pulsed with OVA-Le X and subsequently co-cultured with naive CD4 + CD62L hi OT-II cells. Co-cultures containing OVA-Le X loaded BM-DCs or spDCs contained significantly more IFN-g-producing T cells than those containing OVAloaded DCs ( Figure 3B ). Neither induction of IL-4-nor IL-17A-producing CD4 + T cells was observed ( Figure 3B , upper and middle panel and data not shown). In addition, induction of Foxp3 + T cells was not detected (data not shown). To exclude that the Th1 skewing by OVA-Le X loaded DCs was attributed to the more Th1 prone status of C57BL/6 (Gervais et al., 1984) , we also performed the Th-differentiation assay with cells derived from Th2 prone BALB/c mice (Hsieh et al., 1995) . We observed that naive OVA-specific CD4 + T cells from DO11.10 Tg mice that were stimulated with OVA-loaded BM-DCs differentiated into IL-4 secreting T cells ( Figure 3B , lower panels). However, the generation of IL-4-producing T cells was not influenced by loading DCs with OVA-Le X as these cultures contained comparable percentages of IL-4-producing DO11.10 T cells. Using these Th2-prone T cells, OVA-Le X -pulsed DCs still induced considerably more IFN-g-producing CD4 + T cells than native OVA-pulsed DCs ( Figure 3B , lower panel). Since this assay takes three days longer than the antigen-presentation assay, it is possible that the higher frequency of IFN-g-producing CD4 + T cells is due to increased division of OVA-specific CD4 + T cells. However we found that the amount of proliferation of OVA-specific CD4 + T cells induced by stimulation with OVA-Le X -loaded DCs after 6 days is similar to that induced by OVA-loaded DCs ( Figure 4D ). Cross-presentation of OVA via the MR was shown previously to be dependent on TLR signaling and the presence of high amounts of antigen ( [Burgdorf et al., 2006; Blander and Medzhitov, 2006] and Figure 4-figure supplement 4, left panel) . The observed differences in cross-presentation between OVA and OVA-Le X were not due to any potential contamination with the TLR4 ligand LPS, as both protein preparations did not trigger IL-8 production by TLR4-transfected HEK293 cells (Figure 4-figure supplement 5 ). In addition, both OVA preparations neither induced maturation of BM-DCs nor altered their cytokine production (data not shown). To exclude any potential role of TLR signaling on the MGL1-mediated cross-presentation of OVALe X , we made use of BM-DCs from mice that lack both MyD88 and TRIF (i.e. MyD88/TRIF DKO).
However, MyD88/TRIF DKO BM-DCs still induced more OT-I proliferation when targeted with OVALe X than with OVA ( Figure 4E ) and only a slight reduction of cross-presentation was observed compared to that induced by WT BM-DCs, suggesting a minor role for MyD88-or TRIF-signaling in MGL1-induced cross-presentation. In line with previous findings, neither exogenous loading of 
Cross-presentation induced by MGL1-targeting is independent of TAPtransport and Cathepsin-S -induced endosomal degradation
Several cross-presentation pathways have been described, one of which is dependent on the transport of peptides from the cytosol into MHC-class I loading compartments via TAP-molecules (Amigorena and Savina, 2010; Adiko et al., 2015) , whereas another cross-presentation pathway depends on endosomal degradation by the cysteine protease Cathepsin-S (Shen et al., 2004) . To study a role for TAP transporters in our model, BM-DCs of TAP1 KO and WT control mice were pulsed with OVA-Le X followed by incubation with OT-I T cells. Surprisingly, cross-presentation induced by OVA-Le X was not reduced by the absence of TAP as OT-I proliferation induced by OVALe X -loaded TAP1 KO BM-DCs was not decreased compared to OVA-Le X -loaded WT BM-DC ( Figure 5A ). In accordance with previous publications , we showed that the administration of OVA with LPS is cross-presented in a TAP-dependent manner (Figure 4-figure supplement 2) . Furthermore, the possibility that the results are confounded by reduced levels of MHC-class I on TAP1 KOBM-DCs were excluded as the presentation of exogenously loaded OVA257-264 peptide is equal by both WT and TAP1 KOBM-DCs ( Figure 5A ). In addition, we excluded the involvement of the Cathepsin-S pathway for cross-presentation of OVA-Le X as crosspresentation of OVA-Le X by BM-DCs from Cathepsin-S KO mice (Cat-S KO) was not reduced compared to WT BM-DCs ( Figure 5B ). As expected, the MHC-class II-restricted CD4 + T cell proliferation was compromised in the Cat-S KO BM-DCs (data not shown), illustrating the involvement of Cathepsin-S in cleaving the invariant chain of the MHC-class II molecule (Nakagawa et al., 1999) .
Modification of OVA with LeX alters the intracellular routing of OVA
As the dominant cross-presentation of Le X -modified OVA was neither dependent on TAP nor required TLR signaling, we hypothesized that this may be due to the altered uptake and intracellular routing of OVA in DCs. We therefore used imaging flow cytometry, a method that allows highthroughput image analysis of cells in flow with near-confocal resolution to analyze the intracellular routing of fluorescent labeled OVA-Le X . Co-staining with markers for early endosomal (EEA-1), late endosomal/lysosomal (LAMP1) and recycling endosomal (Rab11) compartments illustrated a swift co-localization of OVA-Le X with EEA1 and Rab11 as shown by high co-localization scores at 15 min ( Figure 6A , Figure 6 -figure supplement 1). However, this co-localization score was strongly decreased at 60 min. At this time-point, higher co-localization scores were detected for OVA-Le X with LAMP1 and Rab11 ( Figure 6B , Figure 6 -figure supplement 2). We then further dissected the intracellular pathway of OVA-Le X using confocal laser scan microscopy (CLSM) and compared it to the intracellular routing of native OVA. We confirmed that native OVA, which internalized via MR, was routed to EEA1 + Rab11 + compartments within 2h ( Figure 6C , upper-left panel and Figure 6C , lower panels + Figure 6-figure supplement 3) . Together, these data suggest that upon internalization, OVA-Le X is rapidly shuttled to Rab11 + EEA1 + compartments from where it moves to Rab11 + LAMP1 + compartments, where it persists for longer periods (i.e. >24h). Thus, these results indicate that internalization via MGL1 allows the antigen to enter the endosomal/lysosomal pathway. The development of early endosome into late endosome/lysosome coincides with a decreasing pH gradient. The pH at which MGL1 dissociates from its ligand is indicative of the compartment in which the antigen becomes available for degradation and loading on MHC-molecules. We therefore analyzed MGL1-binding to its ligand Le X at different pH that resembled the pH of the intracellular compartments. MGL1 starts dissociating from Le X already at pH 6.5 ( Figure 6D ). This indicates that OVA-Le X becomes available for degradation in the early and late endosomal compartments, compartments both associated with cross-presentation. The sustained presence of OVA-Le X in Rab11 + LAMP1 + compartments ( Figure 6B+C ) prompted us to investigate whether these compartments facilitate prolonged cross-presentation, as shown by van Montfoort et al. for OVA-immune complexes (van Montfoort et al., 2009) . Indeed, even two days after antigen pulse, OVA-Le X -loaded DC induced strong expansion of OT-I T cells, suggesting that OVA-Le X -loaded DC have prolonged cross-presentation capacity ( Figure 7A ). At the highest antigen concentration used (i.e. 30 mg/ml), the percentage of proliferated OT-I T cells was only slightly reduced 48 h after pulse compared to that induced by DCs that were pulsed with OVA-Le X for 4 h ( Figure 7A ). Expansion of OT-I T cells driven by 48 h pulse loaded DCs was even detectable at low antigen concentrations (3.75 mg/ml). OT-II proliferation induced by DCs pulsed with OVA-Le X for 48h was also still detectable although less pronounced than the OT-I induced proliferation ( Figure 7B) , suggesting that the prolonged storage of antigen in these intracellular compartments predominantly favored cross-presentation. Taken together, these data suggest that antigen internalized by MGL1 is routed from RAb11 + -EEA1 + compartments towards Rab11 + LAMP1 + compartments, which seem to associate with the extended antigen-processing and cross-presentation.
Discussion
We here demonstrate that the glycosylation-profile of antigens has a major influence on antigen uptake and intracellular compartmentalization, thereby affecting both antigen presentation and the type and strength of the induced immune response. Modification of the model-antigen OVA with Le X glycans directs OVA towards MGL1, skewing naive CD4 + T cell differentiation towards IFNg-producing Th1 cells. Moreover, targeting OVA to MGL1 through the conjugation of Le X , substantially enhanced cross-presentation as revealed by the increased frequency of OVA-specific CD8 + effector T cells in vitro and in vivo. Importantly, MGL1-dependent cross-presentation occurred at low antigen dose and independently of TLR-signaling. Moreover, this cross-presentation pathway did not involve TAP-transporters and Cathepsin-S. MGL1 targeting involved antigen routing to a Rab11 + LAMP1 + compartment in which antigen was present for prolonged periods. Previous studies on CLR-mediated antigen uptake and cross-presentation, in particular by the MR, demonstrated a clear requirement for a TLR ligand (Kovacsovics-Bankowski and Rock, 1995; Sancho et al., 2008; Segura et al., 2009) . A common denominator in some of these studies is that the use of antibody-antigen conjugates could potentially induce a different signal than the natural ligand, due to binding to different part of the receptor or through co-engagement of Fc-receptors. The fact that the addition of Le X glycans to OVA obviates the need for TLR signals for the induction of cross-presentation and Th1 priming in vitro, may indicate that MGL1 signaling is involved in these processes. Some CLR, like DC-SIGN, Clec9A and Dectin-1 are known to induce signaling after triggering by their natural ligands (Geijtenbeek and Gringhuis, 2009; Sancho et al., 2009) . Till now, no signaling pathway has been described for MGL1. Triggering of huMGL resulted in ERK1/2 and NF-kB activation, and results in elevated levels of IL-10 and TNF (Li et al., 2012; van Vliet et al., 2013) . In our studies, the uptake of Le X -modified OVA through MGL1 was not associated with any DC maturation or altered cytokine production by DCs. The fact that OVA-Le X induced an enhanced frequency of Th1 cells in vitro and of antigen-specific effector T cells in vivo when combined with agonistic anti-CD40 Abs illustrates that a yet to be determined costimulatory signal is essential for the induction of effector CD8 + and CD4 + T cells. This powerful function of MGL1 to establish antigen-specific immunity, stands opposite to its recently demonstrated anti-inflammatory function, which include induction of IL-10 production and altered adhesive function by APC (Saba et al., 2009; Westcott et al., 2009 ). Various models for cross-presentation of antigens have been contemplated. The 'cytosolic pathway' of cross-presentation allows receptor-mediated endocytosis or phagocytosis and antigen translocation into the cytosol, where they are degraded into antigenic peptides by the proteasome and transported into the lumen of the endoplasmic reticulum (ER) (Kovacsovics-Bankowski and Rock, 1995; Shen et al., 2004) or ER/phagosomal fusion compartments (Guermonprez et al., 2003; Houde et al., 2003) by TAP-transporters. A variation to the cytosolic pathway was described in which soluble OVA is taken up via the MR and is supplied to stable early endosomal compartments (Burgdorf et al., 2007) . In these compartments, the MHC class I machinery as well as TAPtransporters are selectively recruited, facilitating direct loading of antigen-derived peptides onto MHC class I molecules without trafficking to the ER. The 'vacuolar pathway' allows antigens to be degraded into peptides in early endosomal compartments by endosomal proteases like Cathepsin-S, to be loaded on MHC class I molecules in the same compartment, thus is TAP-independent (Shen et al., 2004) . The current described models for cross-presentation depend on peptide-transport by TAP from the cytosol to either ER or ER/phagosomal fusion compartments or on endosomal degradation of antigens via Cathepsin-S (reviewed in [Amigorena and Savina, 2010; Mintern et al., 2015; Adiko et al., 2015] ). Although we observed localization of OVALe X in early endosomes, absence of either TAP molecules or Cathepsin-S did not influence the enhanced cross-presentation of OVA-Le X . Our data indicate that the MGL1 cross-presentation pathway is different than that of the MR and may occur via antigen storage compartments similar to those described for FcgR-targeted antigens (van Montfoort et al., 2009) . We observed prolonged presence in Rab11 + LAMP1 + compartments in the absence of a maturation stimulus or apparent DC maturation. It is tempting to speculate that in these compartments cross-presentation of OVA is facilitated by Rab11 as it was recently shown that Rab11 activity mediates delivery of MHC-I molecules to phagosomes used for cross-presentation during infection (Nair-Gupta et al., 2014) . However, recruitment of additional components involved in antigen cross-presentation by the SNARE Sec22b40 complex cannot be excluded (Cebrian et al., 2011) . The prolonged antigen cross-presentation via MGL1 allows sustained cross-priming of CD8 + T cells in vivo and thus the efficacy of tumor vaccines that target MGL1 may be higher than of conventional vaccines containing non-targeted antigens.
In the current study, we show that already at very low concentrations, soluble protein antigens are efficiently cross-presented upon uptake by MGL1. DCs pulsed with a low dose of OVA-Le X (7.5 mg/ml) induced significant CD8 + T cell proliferation, whereas the same concentration of native OVA was hardly cross-presented (Figure 4) . Others have demonstrated that native OVA can only be cross-presented when a high dose was used (0.5-1.0 mg/ml) and when accompanied with TLR-triggering Segura et al., 2009) . Although the glycan-modification was associated with increased antigen uptake and enhanced cross-presentation, it did not result in enhanced presentation of antigen on MHC-class II indicating that increased uptake of antigen is not per se a requirement to facilitate MHC class I and II presentation. Therefore, it is most likely that the CLR (and thus the glycosylation of the antigen) dictates how efficiently an antigen is cross-presented. Based on our study, MGL1 cross-presents antigen much more efficiently than the MR. The activity of the glycosylation machinery is subjected to subtle regulation and depends on the cell-type or activation status of the cell. Upon malignant transformation glycan profiles may change dramatically. Le X carbohydrate structures are described to be expressed in the brain (Lieberoth et al., 2009) , and can be de novo expressed on cancer stem cells (Read et al., 2009) or pathogens, and the glycosylation pattern of in vivo accumulating antigens, being brain tissue, tumor tissue or pathogen structure, is crucial for directing specific CLR antigen uptake and cross-presentation (Hittelet et al., 2003; Ohana-Malka et al., 2003) . Although in our studies only two Le X glycans were conjugated to each OVA molecule, it cannot be ruled out that multivalent presentation of Le X , such as often observed on tumors or pathogens (Bergman et al., 2004; Saeland and van, 2011) , may alter avidity-induced MGL-1 signaling and antigen presentation, and induce an anti-inflammatory immune repertoire. At this stage, we do not know whether high glycan valency further enhances or inhibits the MGL1-mediated (cross-)priming. The fact that pulsing of DCs with OVA-Le X resulted in improved cross-priming and Th1-skewing indicates that conjugation of these carbohydrates to tumor-antigens could be beneficial for the induction of potent anti-tumor responses. Therefore, the use of glycans for targeting CLR for anti-cancer immunotherapy could have several advantages. First, they mimic natural function of the receptors, inducing 'natural' signaling cascades in DCs. Furthermore, they are very small molecules, easy to use and relatively cheap to produce. Importantly, many glycans may be considered self-antigens, in contrast to recombinant antibodies that are often not completely of human origin. These properties make it possible to decorate any antigen of choice with glycans to target specific receptors.
In conclusion, our studies indicate that the glycan composition of protein antigens is of fundamental importance in dictating the intracellular routing and Th-skewing, and should be considered as a major determinant in the design of therapeutic vaccines against cancer and infectious diseases.
Materials and methods
Mice C57BL/6 mice (Charles River Laboratories) were used at 8-12 weeks of age. MGL1KO mice, which have a null mutation within the Clec10a gene, are on the C56BL/6 background and were kindly provided through the Consortium for Functional Glycomics. TAP1 KO mice have a null mutation within the Tap1 gene. MGL1 KO, TAP1 KO, OT-I and OT-II TCR transgenic mice were bred in our animal facilities under specific pathogen-free conditions. All experiments were performed according to institutional, state and federal guidelines.
Antibodies and Fc-chimeric constructs
Fluorochrome-conjugated antibodies used: anti-CD11c-APC, anti-IFNg-APC, anti-TNFa-PE-cy7, anti-IL-4-PE, anti-IL17-PE, anti-Foxp3-PE (e-Bioscience, Vienna, Austria), and anti-LAMP-1-v450 (BD-Pharmingen). Unconjugated mouse anti-OVA (Sigma Aldrich), mouse anti-Le X (Calbiochem), rat antimMGL (ER-MP23; kind gift from Dr. P. Leenen, Erasmus MC, Rotterdam, The Netherlands), rat anti-LAMP1 (BD-Pharmingen), rabbit anti-Rab11 (Life Technologies), goat anti-EEA1 (Santa Cruz Biotechnology) and rabbit anti-EEA-1 (Dianova). Secondary antibodies used: peroxidase-labeled F(ab') 2 fragment goat anti-human IgG, F(ab') 2 fragment goat anti-mouse IgG, (Jackson), peroxidase-labeled goat anti-mouse IgM (Nordic Immunology), goat anti-rat Alexa 448, goat anti-rat Alexa 647, donkey anti-goat Alexa 488, donkey anti-goat Alexa 647, donkey anti-rabbit Alexa 555 and donkey anti-rabbit Alexa 488 (Molecular Probes). MGL-1-Fc was generated as described earlier (Singh et al., 2009b) . MR-Fc was kindly provided by L. Martinez-Pomares (University of Nottingham, Nottingham, UK).
Generation of neo-glycoconjugates
Le X (lacto-N-fucopentose III; Dextra Labs, UK) carbohydrate structures were conjugated to OVA (Calbiochem) as previously described (Singh et al., 2009a) . In short; the bifunctional cross-linker (4-Nmaleimidophenyl) butyric acid hydrazide (MPBH; Pierce) was covalently linked to the reducing end of the Le X and the maleimide moiety of the linker was later used for coupling the Le X to OVA. Neoglycoconjugates were separated from reaction by-products using PD-10 desalting columns (Pierce). Additionally, a Dylight 549-N-hydroxysuccimide (NHS) label (Thermo Scientific) was covalently coupled with OVA or OVA-Le X (Dylight-549-OVA). Free label was removed using a PD-10 column (Pierce). The presence of Le X and CLR binding to OVA was measured by ELISA. In brief, OVA-conjugates were coated directly on ELISA plates (NUNC) and binding of MR-Fc, MGL1-Fc, anti-Le X and anti-OVA antibodies to OVA was determined as described (Singh et al., 2009a; Hawiger et al., 2001) . The presence of endotoxin was measured using a LAL assay (Lonza) following manufacturer's protocol.
Glycan analysis
OVA was deglycosylated by incubation in 5 IU of PNGase F (Roche Applied Sciences) o/n at 37˚C. Proteins were extracted by reverse phase chromatography using Sep-Pak Vac C18 disposable cartridges (Waters). Glycans were further purified by reverse phase chromatography using Superclean ENVI-Carb cartridges disposable columns (Supelco). Glycans were lyophilized and re-dissolved in 30 ml of 7-Amino-4-methylcoumarin (160 mM, Sigma Aldrich) and 2-Picoline borane (270 mM, Sigma Aldrich) in DMSO:acetic acid (4:1, Riedel deHaë n). 4-AMC-labelled glycans were purified by size exclusion chromatography using a Bio-Gel P2 (Bio-Rad) column with 50 mM ammonium formate (Sigma Aldrich) as running buffer. 4-AMC-labelled glycans were lyophilized and analyzed by multidimensional normal phase HPLC (UltiMate 3000 nanoLC, Dionex) using a Prevail Carbohydrate ES 0.075 x 200 mm column (Grace) coupled with an LCQ Deca XP with electrospray interface mass spectrometer (Thermo Finnigan) tuned with maltoheptoase (Sigma Aldrich) labeled with 4-AMC and with an intercalated fluorescence detector (Jasco FP-2020 Plus, Jasco) (maximum excitation 350 nm, band width 40 nm; maximum emission 448 nm, band width 40 nm) as previously described .
Molecular weight determination
Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry measurements were done using a 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems). Mass spectra were recorded in the range from to 19,000 to 155,000 m/z in the linear positive ion mode. The data were recorded using 4000 Series Explorer Software and processed with Data Explorer Software version 4.9 (all from Applied Biosystems).
pH dependency of MGL1 binding
The pH dependency of MGL1 binding to Le X on antigens was determined by ELISA. Hereto, Le X -PAA (Lectinity Holdings) was coated onto NUNC Maxisorp plates o/n at RT. The plates were blocked with 1% BSA in TSM buffer (20 mM Tris-HCl; 150 mM NaCl; 2 mM CaCl 2 ; 2 mM MgCl 2 ). After washing, MGL1-Fc was added in TSA with different pH and were kept in this buffer throughout the assay. Binding was detected using peroxidase-labeled F(ab') 2 fragment goat anti-human IgG.
Statistical analysis
Graphpad prism 5.0 was used for statistical analysis. The Student's t-test and one-way ANOVA with Bonferroni correction were used to determine statistical significance. Statistical significance was defined as p< 0.05.
